ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase II, Multicenter, Open-Label, Long-Term Study of the Safety, Tolerability, and Efficacy of Intravenous Natalizumab in Subjects With Rheumatoid Arthritis Who Have Previously Participated in Study ELN100226-RA201

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00831649
Recruitment Status : Terminated (The biological effect seen with natalizumab was not sufficient to warrant further development in RA.)
First Posted : January 29, 2009
Last Update Posted : June 16, 2016
Sponsor:
Collaborator:
Elan Pharmaceuticals
Information provided by (Responsible Party):
Biogen

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Terminated
  Actual Primary Completion Date : February 2005
  Study Completion Date : No date given